SCHEMBL5460698

SCHEMBL5460698

CCN(CC)C(=O)Nc1sc2c(c1C(N)=O)CCOC2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CFTR P13569 1/20 0.59
▸ KIF11 P52732 1/20 0.55
▸ ABCC1 P33527 2/20 0.55
▸ PTPRC P08575 1/20 0.51
▸ PTPN2 P17706 1/20 0.51
▸ PTPN1 P18031 1/20 0.51
▸ PTPRB P23467 1/20 0.51
▸ PTPRE P23469 1/20 0.51
▸ CNR2 P34972 9/20 0.50
▸ FLT3 P36888 2/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ ANO1 Q5XXA6 1/20 0.47
▸ CNR1 P21554 1/20 0.46
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5448448 0.89 CFTR (0.55) CFTRKIF11ABCC1PTPRCPTPN2
SCHEMBL5458844 0.87 CFTR (0.55) CFTRKIF11PTPRCPTPN2PTPN1
SCHEMBL5455685 0.86 CFTR (0.63) CFTRKIF11PTPRCPTPN2PTPN1
SCHEMBL5452201 0.85 CFTR (0.53) CFTRKIF11PTPRCPTPN2PTPN1
SCHEMBL5458923 0.83 CFTR (0.62) CFTRKIF11PTPRCPTPN2PTPN1
SCHEMBL8290653 0.82 CFTR (0.67) CFTRPTPRCPTPN2PTPN1PTPRB
SCHEMBL5449075 0.82 CFTR (0.66) CFTRPTPRCPTPN2PTPN1PTPRB
SCHEMBL5462741 0.81 CFTR (0.62) CFTRKIF11PTPRCPTPN2PTPN1
SCHEMBL5450926 0.81 POLB (0.64) CFTRPTPRCPTPN2PTPN1PTPRB
SCHEMBL5453504 0.81 CFTR (0.62) CFTRKIF11PTPRCPTPN2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 — — US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 — — EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 — — WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885KIF11 4746/4885ABCC1 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback